Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...

Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being recorded. At ...

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...

We think Pfizer’s top line will see growth in the low teens, driven by market share gains for Vyndaqel and Abrysvo.

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

Pfizer’s third-quarter revenue and adjusted profit exceeded expectations, driven by strong sales of its Covid vaccine and ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00.

Reports Q3 revenue $17.7B, consensus $14.95B. Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered another ...

Pfizer (PFE) delivered earnings and revenue surprises of 65.62% and 16.53%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

The drugmaker posted revenue of $17.7 billion in the period, which also topped Street forecasts. Six analysts surveyed by Zacks expected $15.19 billion. Pfizer expects full-year earnings in the range ...

Pfizer’s rebound and McDonald’s E. coli impact headline pre-market earnings; post-close focus shifts to Alphabet and AMD. Get ...